News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Original Publication Date

June 6, 2024

Article Source

External Web Content

On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red…

Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease

Original Publication Date

April 25, 2024

Article Source

External Web Content

Abstract Over the past 10 years, there has been a marked increase in recognition of the interplay between the intestinal microbiome and the hematopoietic system. Despite their apparent distance in the body, a large literature now supports the relevance of the normal intestinal…

Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities

Original Publication Date

April 25, 2024

Article Source

External Web Content

Key Points The number of autoHCT and alloHCT grew faster in Non-Hispanic African Americans and Hispanics compared to Non-Hispanic Whites. Survival after autoHCT and alloHCT improved over time for all racial/ ethnic groups, though African Americans have worse outcomes. There has…

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Original Publication Date

April 21, 2024

Article Source

External Web Content

Key Points SCT from MUD offers superior survival outcomes for severe aplastic anemia compared to both MMUD and Haplo. The decision between a MMUD or Haplo donor in the absence of an available MUD remains uncertain. Selecting the most suitable alternative donor becomes challenging…

Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia

Original Publication Date

September 18, 2023

Article Source

External Web Content

Highlights Haploidentical stem cell transplantation with post-transplantation cyclophosphamide (PTCy-haplo) and umbilical cord blood transplantation (UCBT) achieved similar overall survival in adult patients with aplastic anemia. The rate of neutrophil engraftment was higher in…

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

Original Publication Date

May 3, 2023

Article Source

External Web Content

Key Points In MDS, health-related quality of life (HRQoL) was worse for vulnerable participants and those with worse prognosis. Lower-risk MDS was associated with better HRQoL, but this relationship was lost among the vulnerable. Health-related quality of life (HRQoL) and…

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Original Publication Date

March 17, 2023

Article Source

External Web Content

ABSTRACT PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve…

Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant

Original Publication Date

March 7, 2023

Article Source

External Web Content

A small portion of adults in remission from a deadly blood cancer had persisting mutations detected, which predicted their risk of death from having the cancer return Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from…

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Original Publication Date

September 12, 2022

Article Source

External Web Content

Key Points Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD. Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids. The standard primary treatment for acute graft vs host disease…

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Original Publication Date

August 1, 2022

Article Source

External Web Content

BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration…

We Recommend

For Patients and Families

Your Gift Today Changes Lives

News and Treatment Updates

FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease

Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

We Recommend

Website Feedback

We Recommend

Patient Helpline